Tonix Pharmaceuticals Launches National Campaign on Gastroparesis Impact on Oral Migraine Medications at PAINWeek

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company listed on Nasdaq under the ticker TNXP, has announced a new educational initiative titled "Does Your Migraine Pill Work Every Time?" at the PAINWeek National Conference in Las Vegas. The campaign is designed to inform both patients and healthcare professionals about the benefits of non-oral migraine treatments such as nasal sprays and injectable medications.

Gastroparesis, a condition characterized by delayed stomach emptying, often occurs in conjunction with migraines. This condition can impede the absorption of oral medications, resulting in delayed or insufficient relief from migraine symptoms. Symptoms of gastroparesis include nausea, vomiting, and abdominal pain. Many studies over the past four decades have documented a link between this condition and migraine attacks. 

Dr. Deborah I. Friedman, a neuro-ophthalmologist and headache medicine specialist at the University of Texas Southwestern Medical Center, emphasized the advantages of non-oral migraine treatments. These treatments can provide faster symptom relief, often within just ten minutes, by bypassing the digestive system. She urged patients to consult their clinicians about incorporating these options into their treatment plans.

Shoshana Lipson, Executive Director of Migraine Meanderings™ and Hope for Migraine™, highlighted the importance of patient advocacy in creating effective migraine treatment strategies. Lipson stressed that educating patients about the limitations of oral medications and introducing them to non-oral alternatives could significantly improve their quality of life.

In addition to the educational campaign, Tonix Pharmaceuticals will launch a new website, gpmigraine.com, aimed at patients interested in learning more about gastroparesis and its impact on migraine treatment. The website will provide resources to help patients understand why their oral medications may not be working effectively. 

Migraine Meanderings is also hosting a webinar on September 19, 2024, at 4:00 p.m. EDT titled "Non-Oral Acute Migraine Meds: Could They Make a Difference for You?" The webinar will feature Christopher Gottschalk, MD, FAHS, Director of the Yale Headache Center, and Shoshana Lipson.

Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, reiterated the company's commitment to educating both patients and healthcare providers about gastroparesis and the potential benefits of non-oral migraine treatments. He expressed hope that the campaign would inspire patients to optimize their treatment plans.

Tonix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. The company's portfolio includes TNX-102 SL, which is being developed for the management of fibromyalgia and acute stress reaction. The FDA has granted Fast Track designation to TNX-102 SL for fibromyalgia. Other products in Tonix's pipeline include TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection and autoimmune diseases.

Tonix's commercial subsidiary, Tonix Medicines, markets Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) for the acute treatment of migraines in adults. These products exemplify the company's focus on providing non-oral treatment options to improve patient outcomes.

In summary, Tonix Pharmaceuticals' new educational campaign aims to raise awareness about the benefits of non-oral migraine treatments, particularly for patients suffering from gastroparesis. Through a combination of educational resources, webinars, and an informative website, the company hopes to empower patients and healthcare providers to explore more effective treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!